VI Partners

Buynomics GmbH, founded in 2018 and based in Cologne, Germany, specializes in developing and distributing advanced pricing machine software and related solutions. The company leverages artificial intelligence to transform available data into Virtual Customers, which accurately replicate the purchasing behaviors of real consumers. This innovative approach allows organizations in the consumer-packaged goods and telecommunications sectors to gain instant insights into customer preferences without the need for cumbersome analyses or unreliable focus groups. Buynomics’ platform enables Revenue Growth Management teams to optimize essential commercial decisions, including pricing, promotions, and product mix, by providing a comprehensive understanding of critical revenue levers. Through its holistic methodology, Buynomics delivers actionable insights that support profitable and sustainable business strategies.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Kadoa is an AI-powered no-code platform that allows anyone to build complex data workflows effortlessly.

Oplit is a production planning platform that specializes in providing software solutions designed to enhance the profitability of industrial operations. The company develops integrated, real-time monitoring software that leverages big data and artificial intelligence to optimize production planning across various departments, including production, logistics, and purchasing. Oplit's platform enables manufacturers to centralize, simulate, and visualize their production strategies in real-time, facilitating effective collaboration and informed decision-making. By simulating and comparing different production strategies and tracking progress, Oplit empowers industrial organizations to improve efficiency and drive operational success.

Somagenetix is a biotechnology company specializing in gene therapy aimed at treating phagocyte-related illnesses. The firm focuses on developing innovative treatments for conditions such as immunodeficiency, neurodegeneration, and cancer with brain metastases. By utilizing genetically modified phagocytes, Somagenetix seeks to improve patient outcomes through targeted therapies. Additionally, the company is engaged in the discovery and development of stem cells derived from bone marrow and therapeutic genes from lentiviral vectors. This approach enables the correction of underlying genetic defects and the transplantation of gene-corrected cells back into patients, with the goal of curing various monogenetic diseases. Through its pioneering efforts, Somagenetix aspires to be a leader in the gene therapy sector.

Almer Technologies is a startup focused on developing compact and lightweight augmented reality (AR) glasses aimed at enhancing communication for frontline workers in industrial settings. The company provides an augmented reality platform that integrates hardware and software solutions, enabling users to access critical information and expertise directly in their field of view. By streamlining communication and facilitating remote problem-solving, Almer Technologies aims to reduce downtime and improve efficiency for technical industries.

Flowit provides an end-to-end approach that makes modern, digital HR a breeze allowing organizations to streamline their processes.

XO Life operates a digital platform that facilitates patient education, engagement, and monitoring. It offers services such as real-time treatment tracking, patient feedback analysis, and insights exchange between patients and pharmaceutical companies. The platform aims to enhance medication adherence, improve patient outcomes, and foster better communication between patients and healthcare providers.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

LeaseTeq is a FinTech company focused on transforming the automotive leasing experience through innovative digital solutions. Established in 2021, the company provides a digital leasing platform designed to simplify the leasing process for both individuals and businesses. This platform features a fast and convenient application process that is paperless and environmentally friendly, ensuring discretion and security for its users. LeaseTeq aims to enhance user experience by making leasing more accessible and efficient, leveraging technology to address the traditional challenges associated with leasing in the automotive industry.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

Acodis is a developer of document digitalization software that transforms various types of documents into structured data using advanced artificial intelligence. The company's technology is capable of understanding and processing documents regardless of their format or language, converting complex, unstructured content into valuable, machine-readable data in seconds. This enables businesses to automate their processes, enhance analytics, and efficiently manage information extraction. Acodis offers both standard solutions and customized technologies to meet diverse client needs, allowing seamless integration with existing systems and easy data export through APIs. By streamlining document handling, Acodis significantly reduces the time and resources spent on manual data entry, providing organizations with the tools needed to improve operational efficiency.

Developed, tested, and proven in Germany, Vara is a leading AI-powered breast cancer screening company on a mission to find every deadly breast cancer early. Vara’s Artificial Intelligence (AI) technology is embedded within the German Breast Cancer Screening Program and is backed by some of the most respected institutions in breast cancer screening in the world including Cambridge (UK), Memorial Sloan (US), and Karolinska (Sweden). Vara’s clinical evidence has also been published in Lancet Digital Health, demonstrating that Vara-assisted radiologists significantly outperform average radiologists and are able to find cancers that would otherwise have been missed. Vara works with healthcare stakeholders, radiology service providers, and medical doctor networks to improve access to high-quality screening in Germany, Egypt, India and Mexico.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Sibylla Biotech S.R.L. is an Italian biotechnology company focused on the research and development of innovative solutions for drug design. The company specializes in producing small molecule folding interfering degraders (FIDs) that target various therapeutic areas. Sibylla Biotech employs advanced patent-based software that utilizes algorithms and drug design protocols to enhance drug discovery processes. By implementing original reaction path sampling and data reduction techniques, the software aims to streamline the development of treatments for incurable diseases. In addition to its product development, Sibylla Biotech offers consultancy services in biotechnology and drug development, supporting medical practitioners in rationalizing their research efforts. The company is headquartered in Italy.

Ledgy is a Zurich-based company founded in July 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig. It specializes in developing a valuation tracking platform that facilitates the management of equity capital and employee participation. The platform simplifies the overview of vesting plans, phantom programs, and numbered shares, effectively digitizing the equity management process. By providing clarity and insights into capital tables, funding rounds, and exit negotiations, Ledgy enhances the ability of entrepreneurs and shareholders to make informed decisions regarding their equity assets.

Skribble is an electronic signature platform founded in 2018 and headquartered in Zurich, Switzerland. It provides a legally compliant solution for signing contracts electronically, ensuring that digital signatures carry the same legal weight as handwritten signatures under Swiss and EU law. The platform facilitates the signing process by allowing users to upload documents and manage signatures between parties, all with just a few clicks. Skribble aims to simplify the contract signing experience while maintaining the necessary legal integrity, making it a valuable tool for individuals and businesses seeking efficient document management.

Morgen is a software company that specializes in time management solutions. Its flagship product is an integrated platform designed to consolidate various calendars, tasks, projects, and reminders into a single application. This allows users to efficiently plan, organize, and optimize their schedules, reducing the complexity of managing multiple tools. The platform also includes a native scheduling tool for further streamlining meeting arrangements. Morgen caters to both individual users and teams seeking to enhance their time management capabilities.

Ninox Software GmbH, headquartered in Berlin, Germany, specializes in empowering non-technical teams to automate back-office workflows using its no-code platform. The company enables over 2,800 businesses across various industries to digitize processes without requiring developer assistance. Ninox differentiates itself by offering a user-friendly onboarding experience akin to modern productivity apps, coupled with the flexibility of application platforms, aiming for broader adoption compared to established competitors like Mendix and Outsystems. Its platform provides numerous templates such as CRM, invoicing, project management, and inventory tracking, allowing users to create fully-functional business applications without programming knowledge.

Picterra SA is a Swiss company founded in 2016, headquartered in Écublens. It operates an online platform that leverages artificial intelligence to automate object detection workflows and extract geospatial information from satellite, drone, and aerial imagery. The platform is designed to help users monitor and anticipate environmental changes by providing optimized geo-information. Picterra serves a diverse range of industries, including aerial imaging and mapping, financial services, insurance, journalism, precision agriculture, real estate, utilities, infrastructure, as well as public sector organizations and non-governmental organizations. By facilitating the automatic processing of aerial data, Picterra enables clients to gain crucial insights and make informed decisions based on earth observation imagery.

Founded in 2021 in Zurich, Switzerland, by Swiss entrepreneurs Manuel Grenacher (CEO) and Andreas Hauri (CTO), Unique is a venture-backed B2B SaaS platform that records client conversations and leverages the power of AI to augment client-facing teams with real-time assistance and post-recording insights to build better client relationships and automate routine tasks. Unique cuts out manual work for client advisors by automatically generating a call summary and updating their CRM systems. During client meetings, it identifies key phrases (pain points, product mentions, etc.) to help advisors spot new upselling and cross-selling opportunities.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Acodis is a developer of document digitalization software that transforms various types of documents into structured data using advanced artificial intelligence. The company's technology is capable of understanding and processing documents regardless of their format or language, converting complex, unstructured content into valuable, machine-readable data in seconds. This enables businesses to automate their processes, enhance analytics, and efficiently manage information extraction. Acodis offers both standard solutions and customized technologies to meet diverse client needs, allowing seamless integration with existing systems and easy data export through APIs. By streamlining document handling, Acodis significantly reduces the time and resources spent on manual data entry, providing organizations with the tools needed to improve operational efficiency.

Ledgy is a Zurich-based company founded in July 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig. It specializes in developing a valuation tracking platform that facilitates the management of equity capital and employee participation. The platform simplifies the overview of vesting plans, phantom programs, and numbered shares, effectively digitizing the equity management process. By providing clarity and insights into capital tables, funding rounds, and exit negotiations, Ledgy enhances the ability of entrepreneurs and shareholders to make informed decisions regarding their equity assets.

Oculis Holding AG is a global biopharmaceutical company focused on advancing eye care and preserving vision. The company has developed a novel drug delivery platform that enhances the absorption of therapeutics to both the anterior and posterior segments of the eye. This innovative approach enables the treatment of posterior eye diseases, such as diabetic macular edema, through a simple topical application, thus offering a non-invasive alternative to traditional methods. Oculis's product pipeline includes OCS-01, a topical treatment for diabetic macular edema; OCS-02, a topical biologic for dry eye disease; and OCS-05, a disease-modifying candidate targeting acute optic neuritis and other neuro-ophthalmic disorders, including glaucoma and diabetic retinopathy. Through its cutting-edge technologies and therapeutic candidates, Oculis aims to significantly improve patient outcomes in the field of ophthalmology.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

MedLumics S.L., founded in 2009 and based in Tres Cantos, Spain, specializes in designing and manufacturing catheter-based systems for the treatment of supraventricular tachycardias. The company develops integrated photonic devices that utilize optical coherence tomography technology, a light-based diagnostic method that offers detailed sectional information about tissue. MedLumics' radiofrequency cardiac ablation system provides real-time visual confirmation of catheter contact and stability during tissue ablation. This innovation enhances procedural safety, reduces technical complexity, and lowers recurrence rates for patients undergoing treatment.

HighLife is a medical technology company specializing in Transcatheter Mitral Valve Replacement (TMVR) aimed at treating mitral valve regurgitation. Founded in 2010 by Georg Börtlein, the company is developing a minimally invasive prosthetic mitral valve designed to be implanted on a beating heart, allowing for the preservation of the native valve structure and surrounding anatomy. HighLife's innovative system facilitates a transseptal delivery through the femoral vein, enabling a reversible approach that minimizes trauma to patients during surgical procedures. The technology is currently undergoing clinical evaluation, with a focus on ensuring ease and safety of use for healthcare providers.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Smart Valor AG is a blockchain-based fintech company headquartered in Zug, Switzerland, founded in 2017. It operates as a full-service digital asset provider, offering a retail exchange, asset management, and a technology platform for banks and fintechs. The company facilitates the issuance and distribution of tokenized investment solutions across various asset classes, including real estate, currencies, venture capital, and art. Smart Valor connects banks with a decentralized network of investors and service providers, enhancing the accessibility and liquidity of investments. It also provides essential services related to compliance, know your customer (KYC) processes, and performance tracking in a regulated environment. Recognized for its innovation, Smart Valor has received awards from Swiss governmental agencies and continues to be a leader in the digital asset sector in Switzerland and Liechtenstein.

Gamaya is a company focused on enhancing the efficiency and sustainability of both large-scale and small-holder farming through advanced farmland mapping and diagnostics solutions. It employs patented hyperspectral imaging technology, embedded cameras, and analytical software to convert raw hyperspectral and satellite data into actionable insights for farmers. This innovative approach enables farmers to optimize their use of water, fertilizers, chemicals, and fuel, ultimately improving the quality and quantity of their agricultural production. By facilitating better decision-making, Gamaya's solutions contribute to increased crop yields while minimizing environmental impact, thereby supporting sustainable agriculture and global food security.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Athelas, Inc., founded in 2002 and based in Mountain View, California, develops and manufactures portable blood analysis devices designed for at-home use. The company's technology focuses on monitoring chronically ill patients by providing diagnostic reports from a drop of blood, helping to identify conditions such as leukemia, infections, and inflammatory diseases early. Athelas has deployed an FDA-cleared blood diagnostic device along with other sensors to manage various health metrics including Blood Pressure, Weight, Glucose, and Medication Adherence. The company operates as a subsidiary of MerLion Pharmaceuticals Pte. Ltd.

MESA Imaging specializes in the development and production of advanced 3D time-of-flight cameras. The company designs and markets cameras capable of capturing full 3D images at video frame rates, utilizing the Time-of-Flight (TOF) principle. MESA Imaging's technology, including its proprietary silo pixel architecture and the SR4000 sensor chip, enhances distance measurement capabilities, making it suitable for diverse applications across video gaming, machine vision, automotive, and robotics sectors. Through its innovative products, MESA Imaging aims to provide the image-related industries with state-of-the-art camera systems that meet the growing demand for high-quality 3D imaging solutions.

Ledgy is a Zurich-based company founded in July 2017 by Ben Brandt, Timo Horstschaefer, and Yoko Spirig. It specializes in developing a valuation tracking platform that facilitates the management of equity capital and employee participation. The platform simplifies the overview of vesting plans, phantom programs, and numbered shares, effectively digitizing the equity management process. By providing clarity and insights into capital tables, funding rounds, and exit negotiations, Ledgy enhances the ability of entrepreneurs and shareholders to make informed decisions regarding their equity assets.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

PicoDrill SA is a private company based in Lausanne, Switzerland, specializing in advanced micromachining techniques for creating precise hole structures in various materials, including glass, ceramics, silica, and sapphire. The company has developed a proprietary method known as Electrothermal Focusing, which enables the controlled heating and evaporation of specifically defined volumes in dielectric materials, facilitating the creation of micro-holes and precision cutting. PicoDrill's innovative technologies serve to address the drilling needs within the nanotechnology sector, providing partners and customers with cutting-edge solutions that demonstrate the company's commitment to technology leadership in the industry.

Lambda Health System SA is a Swiss company specializing in the development, production, and commercialization of rehabilitation devices, particularly focusing on the Lambda Robot. This innovative mobilization device is designed to assist individuals recovering from locomotor disabilities, addressing needs in various rehabilitation fields, including neurorehabilitation, orthopedics, and geriatrics. The Lambda Robot enables therapists to conduct exercises without needing to transfer patients between different machines, streamlining the rehabilitation process. Additionally, the company provides the Lambda Control Center, a platform that allows physicians to customize and monitor patient exercises, track progress, and adjust training as needed. The system also incorporates interactive elements such as games and virtual reality applications to enhance cognitive rehabilitation. Founded in 2015 as a spin-off from the University of Applied Sciences of Canton de Vaud, Lambda Health System is headquartered in Yverdon-Les-Bains, Switzerland.

Advanon AG is a financial services platform based in Zurich, Switzerland, that specializes in invoice financing for small and medium-sized enterprises (SMEs). Founded in 2015 by Phil Lojacono, Philip Kornmann, and Stijn Pieper, Advanon connects businesses seeking liquidity with a network of financial investors willing to pre-finance their outstanding invoices. This service allows SMEs to access funds more rapidly, avoiding the lengthy wait times of 30 to 120 days typically associated with customer payments. As an authorized financial intermediary, Advanon is regulated under Swiss law, ensuring compliance with the Anti Money Laundering Act. The platform aims to provide flexible financing solutions with transparent pricing, enabling businesses to enhance their cash flow and support growth without incurring additional obligations.

Flytrex is the largest drone-based food delivery service in the United States, specializing in ultrafast delivery within suburban areas. Operating in North Carolina and Texas, the company delivers food seven days a week and has successfully completed over 120,000 orders for partners including Little Caesars, Papa John's, and El Pollo Loco. Flytrex's innovative drone technology utilizes automated drones controlled via a cloud-based dashboard, optimizing delivery efficiency and significantly reducing costs. This service has lowered suburban delivery expenses from $10 to $1 per package and cut delivery times from 20 minutes to under five. With a 45% monthly retention rate after two years and a high household penetration of 70% within range, Flytrex has garnered strong customer loyalty, reflected in a Net Promoter Score of 75.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Inositec AG, established in 2015 and based in Zurich, Switzerland, is a biotechnology company specializing in the development of novel drugs for soft tissue calcification disorders. It leverages its proprietary Inositune platform, which involves the engineering of inositol phosphate (IP6) analogs by selectively replacing phosphate groups with other chemical groups. This tunable approach enables the creation of molecules with enhanced drug-like properties, tailored for specific therapeutic indications. Inositec's lead programs focus on vascular and renal calcification disorders, including orphan indications, aiming to provide non-antibiotic, toxin-targeted therapies for conditions such as Clostridium difficile infections.

Gamaya is a company focused on enhancing the efficiency and sustainability of both large-scale and small-holder farming through advanced farmland mapping and diagnostics solutions. It employs patented hyperspectral imaging technology, embedded cameras, and analytical software to convert raw hyperspectral and satellite data into actionable insights for farmers. This innovative approach enables farmers to optimize their use of water, fertilizers, chemicals, and fuel, ultimately improving the quality and quantity of their agricultural production. By facilitating better decision-making, Gamaya's solutions contribute to increased crop yields while minimizing environmental impact, thereby supporting sustainable agriculture and global food security.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Equippo is a commercial equipment company that specializes in buying and selling used construction equipment through its online marketplace. Founded in 2014 and headquartered in Zug, Switzerland, the company connects manufacturers, dealers, leasing companies, and other trusted sellers with buyers worldwide, including regions such as South America, Russia, and Poland. Equippo's platform simplifies the process by offering services such as machine inspection, payment management, shipping, trucking, and customs clearance. A notable feature of its service is the Equippo final price calculation engine, which incorporates tariffs, transport, and logistics specific to the buyer's region, making international transactions more straightforward. With a team that can communicate in over nine languages, Equippo aims to facilitate transparent trading in the heavy equipment sector.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

L.E.S.S. SA is a Swiss company, established in 2012 and headquartered in Renens, that specializes in the design and development of ultra-bright and ultra-thin lighting solutions. The company focuses on creating advanced inspection lighting systems, which encompass microscopy lighting and workbench lighting, as well as automotive lighting. L.E.S.S. offers a range of illumination systems, including high and low angle lighting and shadowless solutions, tailored for diverse applications in automotive, machine vision, watchmaking, micromechanics, electronics, medical fields, and harsh environments. Through its innovative approach, L.E.S.S. aims to deliver lighting solutions that combine intense brightness and uniformity within a compact form factor.

UniKey Technologies, Inc. is a provider of innovative access control solutions, specializing in smart locking technologies for residential, commercial, and hospitality applications. Founded in 2010 and headquartered in Winter Park, Florida, the company transforms smartphones into universal electronic keys, allowing users to unlock doors with a simple touch while keeping their devices in pockets or purses. UniKey's patented technology includes features that can assess whether an authorized user is inside or outside a property before granting access, enhancing security and preventing unauthorized entry. The company collaborates with prominent lock manufacturers like Kwikset and Weiser to develop smart locks, notably the Kevo system, and offers a cloud-based lock management solution tailored for multifamily properties and commercial businesses. By delivering advanced smart lock and access control technologies, UniKey addresses a wide range of security needs.

Genkyotex SA is a biopharmaceutical company focused on developing innovative oral small molecule therapies that selectively inhibit NOX enzymes involved in various disease processes, including fibrosis, inflammation, pain, cancer, and neurodegeneration. Its lead candidate, GKT831, targets NOX1 and NOX4 and is currently undergoing Phase II clinical trials for primary biliary cholangitis and type 1 diabetes-related kidney disease. Additionally, Genkyotex is advancing a preclinical candidate, GKT771, which inhibits NOX1 and aims to address pain processing and inflammation. The company also holds a license agreement with the Serum Institute of India for GTL003, an antigen intended for developing combination vaccines against infectious diseases. Established in 2006 and headquartered in Labège, France, Genkyotex is committed to improving treatment options for chronic diseases through its novel therapeutic approaches.

Xeltis AG, established in 2006, is a clinical-stage medical device company based in Zurich, Switzerland, with additional operations in the Netherlands and the USA. The company specializes in developing bio-absorbable heart valves and blood vessels using a proprietary polymer-based technology. Xeltis' RestoreX platform enables the body's natural healing system to develop tissue that replaces the implant, forming a new functional valve or vessel. The company's restorative devices include implantable small diameter blood vessels for hemodialysis and coronary artery bypass graft (CABG) surgery, as well as pulmonary heart valves, with ongoing clinical trials. Xeltis has raised funding from various venture capital firms and European institutions, including a €30 million round in 2021.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sonic Emotion AG is a Swiss company specializing in advanced audio solutions that deliver immersive three-dimensional sound experiences. Founded in 2002 and headquartered in Zurich, the company provides innovative audio technology for a diverse range of applications, including 3D cinemas, events, museums, theme parks, and art installations. Sonic Emotion's proprietary Absolute 3D sound technology enables natural sound reproduction and sound field control, allowing for enhanced auditory experiences with minimal hardware requirements. Additionally, the company offers audio simulation and OEM licensing solutions, as well as the Headquake application, which enhances sound for Apple devices. With research capabilities in France and sales offices across Asia, Sonic Emotion is positioned to meet the growing demand for high-quality audio in various entertainment and commercial sectors.

Edimer Pharmaceuticals is a biotechnology company focused on developing innovative treatments for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as the absence of sweat glands, impaired temperature regulation, respiratory issues, and malformations of hair and teeth. The company's lead product candidate, EDI200, aims to provide significant and lasting improvements in health and quality of life for individuals affected by this condition. Edimer is guided by a team of experienced professionals in the biotechnology sector, supported by a network of distinguished clinical and scientific advisors, all committed to addressing the needs of families impacted by XLHED.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Windeln.de, now known as Nakiki SE, is an online retailer specializing in products for babies, toddlers, children, and young mothers. The company operates in Germany, Austria, Switzerland, the Czech Republic, Spain, and China, offering a diverse range of items, including diapers, baby food, clothing, toys, strollers, child car seats, and baby monitors. Additionally, its product lineup encompasses furniture for children, dietary supplements, and cosmetics, catering not only to younger age groups but also to parents and older children. Windeln.de operates through various segments, including regional online shops and shopping clubs, focusing on providing a comprehensive selection of essential products for families.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.

SmallRivers develops web services that are facilitating the interconnection of people around shared interests. SmallRivers is a privately held startup incorporated in Switzerland (Lausanne) and located on the Swiss Federal Institute of Technology EPFL campus, Scientific Park.

JenaValve Technology, Inc. is a medical device company specializing in the design, development, and manufacturing of transcatheter aortic valve replacement (TAVR) systems for patients with severe aortic regurgitation and aortic stenosis. Founded in 2006 and headquartered in Irvine, California, with additional locations in Munich, Germany, and Leeds, United Kingdom, the company focuses on providing innovative solutions for high-risk patients who may not be suitable candidates for traditional surgical aortic valve replacement. The company's flagship product, the Trilogy™ Heart Valve System, received CE Mark approval in May 2021 and is notable for its dual-disease treatment capabilities. JenaValve's TAVR systems feature a porcine pericardial trileaflet valve mounted on a low-profile nitinol self-expanding frame, designed to engage with the native valve structures for optimal performance. The company has also received Breakthrough Device Designation from the U.S. Food and Drug Administration to facilitate the review of its pivotal trial for the Trilogy Heart Valve System in the United States.

Pay by Shopping is an innovative tool that can be used to reach new customers, increase website traffic, and to raise conversion rates. Available on browser games, via Mobile, and as a Facebook-App, Pay by Shopping enables users to earn virtual currency and items, such as rebates, from a Publisher by shopping at an Advertiser. It drives incremental revenue for Publishers while at the same time serving as a performance marketing tool for online Advertisers. Advertisers gain new customers and see increased sales. Current partnerships include Facebook, OTTO, Zalando, Ubisoft, and Bigpoint. Pay by Shopping is a product of deal united GmbH. The firm is based in Munich with offices in Paris and San Francisco.

SilentSoft is a pioneering company in the Machine to Machine (M2M) sector, established in 2000. It specializes in developing a wide range of technologies and processes for the efficient operation of M2M networks. SilentSoft partners with industrial clients to facilitate the deployment and daily management of these networks. The company focuses on telemetry solutions, providing monitoring devices for tanks and meters. By connecting various objects, SilentSoft enables real-time communication and data exchange, helping clients optimize their operations, reduce emergency deliveries, lower fuel consumption, and decrease carbon dioxide emissions.

CeQur Simplicity is a medical device company focused on improving the lives of people with diabetes. They develop wearable insulin delivery devices that allow users to administer both basal and bolus insulin discreetly and conveniently for up to three days at a time. These devices aim to simplify insulin therapy, reducing the burden of daily injections while enabling patients to experience the benefits of intensive insulin management. CeQur collaborates with healthcare professionals and centers to make these innovative technologies accessible to patients.

Activaero GmbH is a drug delivery company specializing in controlled breathing technologies designed for the pulmonary delivery of inhaled therapeutic agents. Founded in 2004 and based in Gemunden, Germany, with additional locations in Munich and Dublin, Ohio, Activaero develops innovative devices such as AKITA, which utilizes smart card technology for efficient drug delivery, and Watchhaler, specifically designed for children requiring inhaled medication. The company also offers AKITA², a technology for use in clinical trials, and LimiX, a flow limitation valve that regulates inhalation flow rates. In addition to its product offerings, Activaero provides measurement and diagnostic technologies for laboratory applications, including aerosol property measurement systems. Furthermore, the company engages in contract development and clinical trial logistics services, marketing its products through a network of distributors. Activaero's solutions aim to improve therapy outcomes for patients suffering from severe respiratory diseases, including asthma, chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis.

Endosense is a medical technology company dedicated to enhancing the efficacy, safety, and consistency of catheter ablation procedures used to treat cardiac arrhythmias. The company developed the TactiCath, the first and only force-sensing ablation catheter that provides physicians with a real-time and objective measure of contact force during ablation. The TactiCath received the CE mark in May 2009 and has undergone extensive pre-clinical and clinical testing, establishing a strong evidence base for the feasibility and safety of contact force sensing in catheter ablation. Endosense's innovations aim to improve patient outcomes and streamline ablation procedures in the field of cardiology.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Edimer Pharmaceuticals is a biotechnology company focused on developing innovative treatments for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder characterized by symptoms such as the absence of sweat glands, impaired temperature regulation, respiratory issues, and malformations of hair and teeth. The company's lead product candidate, EDI200, aims to provide significant and lasting improvements in health and quality of life for individuals affected by this condition. Edimer is guided by a team of experienced professionals in the biotechnology sector, supported by a network of distinguished clinical and scientific advisors, all committed to addressing the needs of families impacted by XLHED.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

NemeriX SA operates as a fabless semiconductor company that develops ultra-low-power, semiconductors, and software solutions for global positioning system and location-based service products. Its products include analog RF receivers, baseband, and indoor global positioning system integrates chips, as well as global positioning systems based integrated chipset. The company also offers OS support for WinCE, WinMobile, WinXP, LinuX, Symbian, and Nucleus; NeX, an extended ephemeris solution that enables mobile devices to acquire immediate positioning information in difficult garage scenarios and in harshest multi-path environments; SUPL client, which is inter-operated with several independent SUPL servers. In addition, it offers solutions to enable product integration, including evaluation boards, system software reference designs, user documentation, online support, and access to designers and global cadre of application engineers. The company’s product application areas include cellular phones, battery-powered wireless and handheld terminals, personal navigation devices, personal media players, and digital still cameras. It serves proximity-based marketing, social networking, gaming and financial authentication, navigation, tracking, and emergency markets. The company was founded in 2002 and is based in Manno, Switzerland. It has a design center in Cambridge, the United Kingdom; an applications center in Seoul, Korea; a technical center in Taipei, Taiwan; and sales offices in the United States, Europe, Taiwan, and Japan.

Spinelab, based in Winterthur, Switzerland, is a privately held company dedicated entirely to the development of a new generation of spinal motion preservation devices. Spinelab Ltd. is the manufacturer and distributor of the CE-marked implant and instrument system Elaspine™ for the treatment of degenerative lumbar spine disease.

Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.

Sequana Medical is a Swiss medical device company based in Zurich that specializes in developing and commercializing implantable pump systems to manage fluid balance within the body. The company's flagship product, the Alfapump System, is designed to automatically and continually remove ascites, which is excess fluid that accumulates in the abdominal cavity due to advanced liver disease, certain cancers, or congestive heart failure. This system moves the excess fluid to the bladder for natural elimination through urination. Sequana Medical's technology also has potential applications in managing pleural effusions in lung disease patients and fluid overload in those with end-stage renal disease and congestive heart failure. The company was founded in 2006 and has additional offices in Munich, Germany.

ESBATech, founded in 1998 as a spin-out from the University of Zurich, specializes in developing fully human antibody fragments for therapeutic use. The company utilizes its proprietary single-chain antibody frameworks to create product candidates targeting clinically relevant sites. ESBATech's approach aims to deliver high concentrations of these therapeutic fragments directly to targeted areas while minimizing systemic exposure, thereby reducing the risk of adverse drug reactions through topical and local administration methods.

Mobileye is a leader in the development and deployment of advanced driver-assistance systems (ADAS) and autonomous driving technologies. The company specializes in creating a comprehensive portfolio of solutions that include both software and hardware components, designed to enhance vehicle safety and pave the way for future autonomous driving capabilities. Its offerings range from driver assistance tools to fully autonomous systems, such as Mobileye Chauffeur and Mobileye Drive. In addition to its core technologies, Mobileye provides data services aimed at optimizing maintenance operations and improving mobility infrastructure. With a strong foundation in computer vision, machine learning, mapping, and data analysis, Mobileye plays a pivotal role in shaping the future of transportation.

EndoArt is a synthetic implant that treats corneal edema by establishing a new form of corneal availability, hence protecting vision and restoring function.

Nexthink, established in 2004, specializes in digital experience management, focusing on the end-user perspective. Headquartered in Switzerland with global operations, the company offers a real-time analytics platform that transforms endpoint data into actionable insights. This enables organizations to enhance business productivity, manage incidents and changes effectively, and measure digital workplace experience using the Digital Experience Score system. Nexthink serves a diverse range of industries, including finance, healthcare, and manufacturing, empowering IT teams to create highly productive digital workplaces for employees.

Visonys develops information security software for financial institutions, e-commerce, industrial companies, and authorities. It offers visonysAirlock, which provides differing authorization to clients, partners, and employees for relevant applications. The company's products are used in Web applications that process confidential information or manage business transactions and processes. The company was founded in 2002 as Seclutions AG and changed its name to Visonys AG in February, 2006. The company is based in Zurich, Switzerland.